The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...

The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk's popular weight-loss and ...

The shortage of Novo Nordisk’s (NVO) blockbuster weight loss drugs has been resolved, according to the U.S. Food and Drug Administration ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ...

Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...

The FDA declared the end of the shortage of Novo Nordisk’s Wegovy and Ozempic, impacting compounding pharmacies selling ...

Novo Nordisk A/S’s weight-loss and diabetes drugs are no longer in short supply, US regulators said, a decision that’s ...

Semaglutide is a glucagon-like peptide-1 (GLP-1) that helps regulate blood sugar levels. Because of outsized demand for ...

The FDA announcement confirms that the U.S. supply of both prescription-only drugs now meets or exceeds the current and projected demand in the country, the Danish pharmaceutical company said.

The Food and Drug Administration announced Friday it had officially declared an end to the nationwide shortage of Ozempic and Wegovy, medications used for diabetes and weight loss. The agency first ...

Shares of obesity-drug maker Novo Nordisk rose Friday after the Food and Drug Administration declared that the company’s popular medications Ozempic and Wegovy were no longer in shortage. A shortage o ...